We are dead in 15 months

Quote
Anonymous said:
Many times and was burned 50% of them. They are years behind the current pack of HCV leaders and won't catch up. All of the HCV players are quite obvious now. Those like Idenix who are years behind and yet talked about as if the will be relevant in the market are no different than the Sirens on the Island of FaiaKes. Do you know this story?
Click to expand...

Sure, that's why S eth k larman raised his stake Friday to 27.55% and Novartis still owns 25% and TR price still owns 11% and Bain Capital still owns 10%. Seems like a real Dog!
 






Anonymous said:
Sure, that's why S eth k larman raised his stake Friday to 27.55% and Novartis still owns 25% and TR price still owns 11% and Bain Capital still owns 10%. Seems like a real Dog!
Click to expand...

Are we talking about the same company? Do you know their history?? IDIX has a history of peaking and then dropping lower. They once sat at over $25/share not too many years ago and even last year were over $14/share. Now someone is supposed to be excited about barely breathing above $4/share and a sub-par Nuc? Look at the studies and try and find relevance in 2014's market.

These same investors that you mentioned keep losing their shirts and haven't learned to quit. It's embarrassing for them.

Do you remember the fall of 2010 when they were soaring like every other company in the HCV race only to have the FDA halt two drugs because they were poisoning people? They then clawed their way back only to crush investors once again because the FDA halted the guanasines. Now a lot of greedy people who don't understand timelines or the importance of efficacy (or potency) are reinvesting in IDIX thinking that the days of prospecting for small cap HCV biotechs is still going to produce.

IDX19368 IDX320 and IDX184?

You nailed it-->DOG
 






Anonymous said:
Are we talking about the same company? Do you know their history?? IDIX has a history of peaking and then dropping lower. They once sat at over $25/share not too many years ago and even last year were over $14/share. Now someone is supposed to be excited about barely breathing above $4/share and a sub-par Nuc? Look at the studies and try and find relevance in 2014's market.

These same investors that you mentioned keep losing their shirts and haven't learned to quit. It's embarrassing for them.

Do you remember the fall of 2010 when they were soaring like every other company in the HCV race only to have the FDA halt two drugs because they were poisoning people? They then clawed their way back only to crush investors once again because the FDA halted the guanasines. Now a lot of greedy people who don't understand timelines or the importance of efficacy (or potency) are reinvesting in IDIX thinking that the days of prospecting for small cap HCV biotechs is still going to produce.

IDX19368 IDX320 and IDX184?

You nailed it-->DOG
Click to expand...

"Now a lot of greedy people who don't understand timelines or the importance of efficacy (or potency) are reinvesting in IDIX thinking that the days of prospecting for small cap HCV biotechs is still going to produce"......Yes, like The Baupost Group. The 3rd most successful Hedge Fund in the world. Idiots!!
 






Anonymous said:
"Now a lot of greedy people who don't understand timelines or the importance of efficacy (or potency) are reinvesting in IDIX thinking that the days of prospecting for small cap HCV biotechs is still going to produce"......Yes, like The Baupost Group. The 3rd most successful Hedge Fund in the world. Idiots!!
Click to expand...

They just raised their stake from 19.98% to 27.55% on Friday. Idiots!

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
36,910,868
 












Anonymous said:
"Now a lot of greedy people who don't understand timelines or the importance of efficacy (or potency) are reinvesting in IDIX thinking that the days of prospecting for small cap HCV biotechs is still going to produce"......Yes, like The Baupost Group. The 3rd most successful Hedge Fund in the world. Idiots!!
Click to expand...

Yes idiots. These people will see history repeats itself. Look at the studies-YOURSELF. Don't go on what in these dummy investors think. They aren't scientists. They are speculators banking on an old theory that IDIX has the only Nuc left in the stable and someone is going to want it. If that was the case they would have been gobbled up not long after INHX and VRUS were. It didn't happen-for a reason. The drug isn't very good compared to other nucs- is slower and less efficacious- and far behind the competition.

You nailed it again. Idiots.
 












Anonymous said:
They just raised their stake from 19.98% to 27.55% on Friday. Idiots!

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
36,910,868
Click to expand...

This guy is a wall street wannabe troll. He's posting about Idenix on all the companies threads who have a horse in the HepC race to drum up comments and support. Miserable daytraders...
 






Anonymous said:
This guy is a wall street wannabe troll. He's posting about Idenix on all the companies threads who have a horse in the HepC race to drum up comments and support. Miserable daytraders...
Click to expand...

total JERK! probably wants to fool everybody into buying this POS. Doesn't everybody know that:
Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects -ClinicalTrials.gov Identifier:NCT01974687

just started and was posted on Clinical trails . gov and that the trail deals with 136 patients which is more than ANY OTHER phase 1/2a for ANY OTHER HCV drug EVER!!!!

and that... Its for the toughest to treat population of G1-6 and cirrhotics

and that... when its done they go for phase 2b/3 with their wholly owned pan-genotypic next generation NS5a that will rival Gileads: SOF+GS-5816

What a jerk!!!
 






Anonymous said:
total JERK! probably wants to fool everybody into buying this POS. Doesn't everybody know that:
Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects -ClinicalTrials.gov Identifier:NCT01974687

just started and was posted on Clinical trails . gov and that the trail deals with 136 patients which is more than ANY OTHER phase 1/2a for ANY OTHER HCV drug EVER!!!!

and that... Its for the toughest to treat population of G1-6 and cirrhotics

and that... when its done they go for phase 2b/3 with their wholly owned pan-genotypic next generation NS5a that will rival Gileads: SOF+GS-5816

What a jerk!!!
Click to expand...

and that NOBODY CAN BUY THAT COMPANY BECAUSE ITS 73% owned by 4 parties (Seth klarman, Novartis, Bain capital & TR Price) and they don't care what the stock price is... only what its going to get bought out for?

What a jerk!!!
 






Anonymous said:
total JERK! probably wants to fool everybody into buying this POS. Doesn't everybody know that:
Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects -ClinicalTrials.gov Identifier:NCT01974687

just started and was posted on Clinical trails . gov and that the trail deals with 136 patients which is more than ANY OTHER phase 1/2a for ANY OTHER HCV drug EVER!!!!

and that... Its for the toughest to treat population of G1-6 and cirrhotics

and that... when its done they go for phase 2b/3 with their wholly owned pan-genotypic next generation NS5a that will rival Gileads: SOF+GS-5816

What a jerk!!!
Click to expand...

Is he telling you that "nucs" can be used for Oncology if your IP Library is "large" enough and not just leased ALS-2200 & ALS-2158 from Larry Blatts company?
 






Anonymous said:
Is he telling you that "nucs" can be used for Oncology if your IP Library is "large" enough and not just leased ALS-2200 & ALS-2158 from Larry Blatts company?
Click to expand...

and that part of the reason that GILD paid so much was not just for SOF but for Pharmasetts "library" of "nucs" because they want to get into "oncology" so bad in the future?
 






Anonymous said:
and that part of the reason that GILD paid so much was not just for SOF but for Pharmasetts "library" of "nucs" because they want to get into "oncology" so bad in the future?
Click to expand...

Must be a "wall-street Troll" or some other "loser" . Oh, I did forget about IDIX's patent infringement lawsuit with Gilead over "SOF". and "No" its not "over"
 


















Top Bottom
Back
Quote